Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...
Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...
Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...
CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling ...
The "Mad Money" host revisits a stock he spent years dismissing.
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...
24/7 Wall St. on MSN
Six dividend aristocrats keeping SCHD’s income stream bulletproof this year
Quick ReadSCHD has delivered 227% over 10 years and screens every holding for 10 consecutive years of dividend payments ...
Akeso's rise reflects the broader expansion of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay ...
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results